Characteristics of relapsed/refractory diffuse large B‐cell lymphoma patients with durable responses to maveropepimut‐S, pembrolizumab, and cyclophosphamide: Long‐term follow‐up from the SPiReL trial
Combination immunotherapy regimens such as this could offer a promising alternative to other treatments with significant toxicities for select patients.
Authors
- Pierre Laneuville (ORCID: https://orcid.org/0000-0002-7031-4297)
- Yidi Jiang (ORCID: https://orcid.org/0000-0001-9013-0869)
- Isabelle Bence‐Bruckler (ORCID: https://orcid.org/0000-0002-0468-0280)
- Gail Klein
- George Tomlinson (ORCID: https://orcid.org/0000-0002-9328-6399)
- Joy Mangel (ORCID: https://orcid.org/0000-0002-1364-5030)
- Neil L. Berinstein (ORCID: https://orcid.org/0000-0001-7251-4252)
- Arjun Pandey (ORCID: https://orcid.org/0000-0001-5529-3857)
- Nick Forward
- Douglas A. Stewart (ORCID: https://orcid.org/0000-0001-5531-0960)
- Kathryn Mangoff
- Kim Roos
Institutions
- Sunnybrook Health Science Centre (CA)
- University Health Network (CA)
- Queen Elizabeth II Health Sciences Centre (CA)
- London Health Sciences Centre (CA)
- McGill University Health Centre (CA)
- Health Sciences Centre (CA)
- Baker Hughes (Canada) (CA)
- Sunnybrook Hospital (CA)
- Sunnybrook Research Institute
Publication Details
- Journal
- eJHaem
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1002/jha2.1062
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- McGill University
- London Health Sciences Centre
- Ottawa Hospital Research Institute
- McGill University Health Centre
- Merck Canada